MAPK3 and colorectal carcinoma: We analysed ERK1/2 activation in the Caco-2 cell line (the only BRAF and KRAS wild-type cells in our CRC panel with an intact MAPK pathway [23]) after NMU-9 and NMUR2 agonist treatment.